Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib (SAVANNAH)

A Phase II Study Assessing the Efficacy of Osimertinib in Combination With Savolitinib in Patients With EGFRm+ and MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Treatment With Osimertinib.

This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib

Study Overview

• Status: Active, not recruiting
• Conditions: Carcinoma
• Intervention / Treatment: Drug: osimertinib; Drug: savolitinib; Drug: placebo

Detailed Description

The combination of osimertinib with savolitinib in this study (the SAVANNAH study) will explore if the combination will overcome MET-amplification as a mechanism of resistance. The SAVANNAH study will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET-amplified/overexpressed, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib.

Eligible patients will be those with histologically or cytologically confirmed diagnosis of EGFRm+, MET amplified/overexpressed (FISH10+ and/or IHC90+) NSCLC that is locally advanced or metastatic and is not amenable to further surgery or radiotherapy with curative intent. The disease must have progressed following treatment with first line osimertinib. Patients must have confirmation of MET-amplified/overexpressed tumour by central FISH and IHC testing (requirements summarised in the main body of the protocol and fully explained in the Central Laboratory Manual). Patients must not have received prior or current treatment with savolitinib or another MET inhibitor.

All patients confirmed as eligible will begin treatment on Day 1 with osimertinib + savolitinib combination therapy or placebo to osimertinib + savolitinib. Treatment will continue in 28 day cycles until either objective disease progression by investigator per RECIST 1.1 is assessed, unacceptable toxicity occurs, consent is withdrawn or another discontinuation criterion is met.

• Study Type: Interventional
• Enrollment (Actual): 367
• Phase: Phase 2

Contacts and Locations

Study Locations

• Brazil
  • Barretos, Brazil, 14784-400
    • Research Site
  • Curitiba, Brazil, 80810-050
    • Research Site
  • Goiânia, Brazil, 74093-300
    • Research Site
  • Porto Alegre, Brazil, 90610-000
    • Research Site
  • Porto Alegre, Brazil, 90540-140
    • Research Site
  • Rio de Janeiro, Brazil, 22271-110
    • Research Site
  • Salvador, Brazil, 41950-640
    • Research Site
  • São José do Rio Preto, Brazil, 15090-000
    • Research Site
  • São Paulo, Brazil, 01246-000
    • Research Site
  • São Paulo, Brazil, 01509-900
    • Research Site
• Canada
  • Alberta
    • Calgary, Alberta, Canada, T2N 5G2
      • Research Site
    • Edmonton, Alberta, Canada, T6G 1Z2
      • Research Site
  • Ontario
    • Newmarket, Ontario, Canada, L3Y 2P9
      • Research Site
    • North York, Ontario, Canada, M2K 1E1
      • Research Site
    • Toronto, Ontario, Canada, M5G 2M9
      • Research Site
    • Toronto, Ontario, Canada, M4N 3M5
      • Research Site
• Chile
  • Santiago, Chile, 7520349
    • Research Site
  • Santiago, Chile, 7500713
    • Research Site
  • Santiago, Chile, 8420383
    • Research Site
• Denmark
  • Aalborg, Denmark, 9100
    • Research Site
  • Herlev, Denmark, 2730
    • Research Site
  • København Ø, Denmark, 2100
    • Research Site
  • Næstved, Denmark, 4700
    • Research Site
  • Odense, Denmark, 5000
    • Research Site
  • Vejle, Denmark, 7100
    • Research Site
• France
  • Dijon, France, 21079
    • Research Site
  • Marseille, France, 13915
    • Research Site
  • Nantes, France, 44093
    • Research Site
  • Paris, France, 75020
    • Research Site
  • Paris, France, 75248
    • Research Site
  • Rennes, France, 35033
    • Research Site
• India
  • Bangalore, India, 560064
    • Research Site
  • Chennai, India, 600035
    • Research Site
  • Kolkata, India, 700160
    • Research Site
  • New Delhi, India, 110085
    • Research Site
• Italy
  • Avellino, Italy, 83100
    • Research Site
  • Florence, Italy, 50134
    • Research Site
  • Milan, Italy, 20141
    • Research Site
  • Milan, Italy, 20133
    • Research Site
  • Orbassano, Italy, 10043
    • Research Site
  • Padova, Italy, 35128
    • Research Site
  • Parma, Italy, 43126
    • Research Site
  • Perugia, Italy, 06132
    • Research Site
  • Peschiera del Garda, Italy, 37019
    • Research Site
• Japan
  • Fukuoka, Japan, 812-8582
    • Research Site
  • Hiroshima, Japan, 730-8518
    • Research Site
  • Kanazawa, Japan, 920-8641
    • Research Site
  • Nagoya, Japan, 464-8681
    • Research Site
  • Niigata, Japan, 951-8566
    • Research Site
  • Sapporo, Japan, 003-0804
    • Research Site
  • Sayama, Japan, 589-8511
    • Research Site
  • Sunto-gun, Japan, 411-8777
    • Research Site
  • Wakayama, Japan, 641-8510
    • Research Site
  • Yokohama, Japan, 241-0815
    • Research Site
• South Korea
  • Goyang-si, South Korea, 10408
    • Research Site
  • Seongnam-si, South Korea, 13620
    • Research Site
  • Seoul, South Korea, 03080
    • Research Site
  • Seoul, South Korea, 03722
    • Research Site
  • Seoul, South Korea, 05505
    • Research Site
  • Seoul, South Korea, 06351
    • Research Site
  • Suwon, South Korea, 16247
    • Research Site
• Spain
  • Córdoba, Spain, 14004
    • Research Site
  • Donostia / San Sebastian, Spain, 20014
    • Research Site
  • Madrid, Spain, 28046
    • Research Site
  • Madrid, Spain, 28041
    • Research Site
  • Málaga, Spain, 29010
    • Research Site
  • Valencia, Spain, 46026
    • Research Site
  • Zaragoza, Spain, 50009
    • Research Site
• Taiwan
  • Hsinchu, Taiwan, 300
    • Research Site
  • Kaohsiung City, Taiwan, 83301
    • Research Site
  • New Taipei City, Taiwan, 23561
    • Research Site
  • Taichung, Taiwan, 40705
    • Research Site
  • Taichung, Taiwan, 402
    • Research Site
  • Tainan, Taiwan, 70403
    • Research Site
  • Taipei, Taiwan, 10002
    • Research Site
  • Taipei, Taiwan, 112
    • Research Site
  • Taoyuan District, Taiwan, 333
    • Research Site
• United States
  • California
    • La Jolla, California, United States, 92093
      • Research Site
    • Los Angeles, California, United States, 90024
      • Research Site
    • Sacramento, California, United States, 95817
      • Research Site
  • District of Columbia
    • Washington D.C., District of Columbia, United States, 20016
      • Research Site
  • Maryland
    • Baltimore, Maryland, United States, 21201
      • Research Site
  • Massachusetts
    • Boston, Massachusetts, United States, 02215
      • Research Site
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Research Site
  • New York
    • Brooklyn, New York, United States, 11220
      • Research Site
  • Pennsylvania
    • Philadelphia, Pennsylvania, United States, 19111
      • Research Site
    • Pittsburgh, Pennsylvania, United States, 15232
      • Research Site
  • Washington
    • Seattle, Washington, United States, 98109
      • Research Site
• Vietnam
  • Ho Chi Minh City, Vietnam, 700000
    • Research Site
  • Hà Nội, Vietnam, 100000
    • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion criteria:

• Patients must be ≥18 years of age (≥20 years of age in Japan). All genders are permitted.
• Histologically or cytologically confirmed locally advanced or metastatic EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity and permitted in the osimertinib national label (such as either exon 19 deletion and/or L858R) which is not amenable to curative therapy.
• Documented radiologic disease progression on 1L osimertinib.
• MET amplification and/or overexpression (FISH10+ and/or IHC90+) as determined by FISH (central) and IHC (central) testing on tumour sample collected following progression on 1L osimertinib treatment.
• Available tumour sample for central MET FISH and IHC analysis or willingness to collect additional sample for central testing which fulfils the following requirements:

Obtained following progression on previous osimertinib therapy;

obtained within 2 years of submission for MET analysis;

sufficient tissue to meet the minimum tissue requirement defined in the current Laboratory Manual.

• At least 1 lesion, not previously irradiated, not biopsied during the screening period, that can be accurately measured at baseline as ≥10 mm in the longest diameter (except lymph nodes which must have short axis ≥15 mm) with CT or MRI which is suitable for accurate repeated measurements. If only 1 measurable lesion exists, it is acceptable to be used as long as baseline tumour assessment scans are done at least 14 days after the screening tumour sample collection is performed.
• Prior lines of therapy in locally advanced/metastatic setting: Only prior 1L osimertinib treatment in metastatic setting is permitted.
• Adequate haematological function defined as:
• Absolute neutrophil count ≥1500/μL
• Haemoglobin ≥9 g/dL (no transfusion in the past 2 weeks)
• Platelets ≥100,000/μL (no transfusion in the past 10 days)
• Adequate liver function
• ALT, AST ≤2.5 x ULN with TBL ≤ ULN OR
• TBL >ULN to ≤1.5x ULN with ALT and AST ≤ ULN
• Adequate renal function - defined as a serum creatinine <1.5 times the institutional ULN OR a glomerular filtration rate ≥50 mL/min. Confirmation of creatinine clearance is only required when creatinine is only required when creatinine is >1.5 times ULN.
• Adequate coagulation parameters: INR <1.5 and activated partial thromboplastin time <1.5 x ULN unless patients are receiving therapeutic anti coagulation which affects these parameters.
• Patients with known tumour thrombus or deep vein thrombosis are eligible if clinically stable on low molecular weight heparin for ≥2 weeks. The use of direct oral anticoagulants such as apixaban/rivaroxaban will be accepted as treatment for cancer related thromboembolism treatment. The use of warfarin for oral anticoagulation is not recommended.
• ECOG/WHO performance status of 0 or 1 with no deterioration over the previous 2 weeks and a minimum life expectancy of 12 weeks.
• Females must be using highly effective contraceptive measures, should not be breast feeding and must have a negative pregnancy test if of childbearing potential, or must have evidence of non-childbearing potential.
• Males with a female partner of childbearing potential should be willing to use barrier contraception during the study and for 6 months following discontinuation of study drug.

Exclusion Criteria:

• Unresolved toxicities from any prior therapy greater than CTCAE Grade 1 at the time of starting study treatment with the exception of alopecia and Grade 2 prior platinum therapy related neuropathy.
• As judged by the investigator, active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (eg, ulcerative disease, uncontrolled nausea, vomiting, diarrhoea Grade ≥2, malabsorption syndrome or previous significant bowel resection).
• Any of the following cardiac diseases currently or within the last 6 months:

Unstable angina pectoris

Congestive heart failure (New York Heart Association [NYHA] ≥Grade 2)

Acute myocardial infarction

Stroke or transient ischemic attack

Uncontrolled hypertension (blood pressure [BP] ≥150/95 mmHg despite medical therapy).

Mean resting correct QT interval (QTcF) >470 msec for women and >450 msec for men at Screening, obtained from 3 ECGs using the screening clinic ECG machine derived QTcF value.

Any factors that may increase the risk of QTcF prolongation or risk of arrhythmic events such as heart failure, chronic hypokalaemia not correctable with supplements, congenital or familial long QT syndrome, family history of unexplained sudden death under 40 years of age in first-degree relatives or any concomitant medication known to prolong the QT interval and cause Torsade de Pointes.

Any clinically important abnormalities in rhythm, conduction or morphology of resting ECGs, eg, complete left bundle branch block, third degree heart block, second degree heart block, P-R interval >250 msec.

Acute coronary syndrome

• Wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) administered ≤28 days or limited field radiation for palliation ≤7 days prior to starting study drug or has not recovered from side effects of such therapy.
• Major surgical procedures ≤28 days of beginning study drug or minor surgical procedures ≤7 days
• Evidence of severe or uncontrolled systemic diseases, including renal transplant, active bleeding diatheses or uncontrolled hypertension, which in the investigator's opinion makes it undesirable for the patient to participate
• Active hepatitis B or C or known serious active infection e.g. tuberculosis or human immunodeficiency virus. Viral testing is not required for assessment of eligibility for the study.
• Known serious active infection including, but not limited to, tuberculosis, or human immunodeficiency virus (positive human immunodeficiency virus 1/2 antibodies).
• Presence of other active cancers, or history of treatment for invasive cancer, within the last 5 years. Patients with Stage I cancer who have received definitive local treatment at least 3 years previously, and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (ie, non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.
• Spinal cord compression or brain metastases unless asymptomatic, stable and not requiring steroids for at least 2 weeks prior to start of study treatment.
• Past medical history of interstitial lung disease(ILD), drug-induced ILD, radiation pneumonitis which required steroid treatment, or any evidence of clinically active ILD.
• History of liver cirrhosis of any origin and clinical stage; or history of other serious liver disease or chronic disease with relevant liver involvement, with or without normal LFTs,
• Prior or current treatment with a 3rd generation EGFR-TKI other than osimertinib
• Prior or current treatment with savolitinib or another MET inhibitor (eg, foretinib, crizotinib, cabozantinib, onartuzumab, capmatinib).
• Any cytotoxic chemotherapy, investigational agents or other anticancer drugs for the treatment of advanced NSCLC from a previous treatment regimen or clinical study within 14 days prior to the first dose of study treatment with the exception of monotherapy osimertinib which may continue uninterrupted during screening.
• Patients currently receiving (or unable to stop use prior to receiving the first dose of study treatment) medications or herbal supplements known to be strong inducers of CYP3A4, strong inhibitors of CYP1A2 within 3 weeks of the first dose of study treatment (including St John's Wort).
• Participation in another clinical study with a cytotoxic, investigational product (IP), or other anticancer drug for the treatment of advanced NSCLC if received IP from that study within 14 days of the first dose of study treatment.
• Known hypersensitivity to the active or inactive excipients of osimertinib or savolitinib or drugs with a similar chemical structure or class.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: osimertinib + savolitinib	Drug: osimertinib; osimertinib (80 mg oral OD).; Drug: savolitinib; savolitinib (300 mg oral OD or 300 mg oral BID or 600 mg oral OD)
Placebo Comparator: placebo + savolitinib	Drug: savolitinib; savolitinib (300 mg oral OD or 300 mg oral BID or 600 mg oral OD); Drug: placebo; placebo to osimertinib (oral OD)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR) by Investigator Assessment; Target Population Analysis Set	Percentage of subjects with a confirmed Objective Response (OR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). OR includes Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in target lesion diameters). OR must be recorded at one visit and confirmed by repeat imaging at least 4 weeks later, with no disease progression between initial and confirmation visits.	Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years.
Objective Response Rate (ORR) by Investigator Assessment; 300 mg QD Safety Analysis Set	Percentage of subjects with a confirmed Objective Response (OR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). OR includes Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in target lesion diameters). OR must be recorded at one visit and confirmed by repeat imaging at least 4 weeks later, with no disease progression between initial and confirmation visits.	Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progression until the end of the study, or an approximate maximum of 5.6 years.

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Objective Response Rate (ORR) by BICR Assessment; Target Population Analysis Set	Percentage of subjects with a confirmed Objective Response (OR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). OR includes Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in target lesion diameters). OR must be recorded at one visit and confirmed by repeat imaging at least 4 weeks later, with no disease progression between initial and confirmation visits.	Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progression until the end of the study, or an approximate maximum of 5.6 years.
Duration of Response (DoR) by Investigator Assessment; Target Population Analysis Set	Median time of response for patients with an investigator assessed confirmed objective response per RECIST1.1	From date of first confirmed objective response to progressive disease in accordance with RECIST1.1 or death from any cause, whichever came first; assessed for up to 5.6 years.
Duration of Response (DoR) by BICR Assessment; Target Population Analysis Set	Median time of response for patients with an investigator assessed confirmed objective response per RECIST1.1	From date of first confirmed objective response to progressive disease in accordance with RECIST1.1 or death from any cause, whichever came first; assessed for up to 5.6 years.
Progression-free Survival (PFS) by Investigator Assessment; Target Population Analysis Set	Median progression-free survival (PFS) was measured by investigator assessment using RECIST 1.1 and the Kaplan-Meier method. Progressive disease (PD) per RECIST 1.1 is defined as at least a 20% increase in the sum of target lesion diameters (with an absolute increase of ≥5 mm); unequivocal progression of non-target lesions, which may result from marked progression in a single lesion or multiple lesions; or the appearance of one or more unequivocal new lesions.	Time from randomization/start of study treatment to investigator assess progressive disease per RECIST1.1 or death, assessed for up to 5.6 years.
Progression-free Survival (PFS) by BICR Assessment; Target Population Analysis Set	Median progression-free survival (PFS) was measured by BICR assessment using RECIST 1.1 and the Kaplan-Meier method. Progressive disease (PD) per RECIST 1.1 is defined as at least a 20% increase in the sum of target lesion diameters (with an absolute increase of ≥5 mm); unequivocal progression of non-target lesions, which may result from marked progression in a single lesion or multiple lesions; or the appearance of one or more unequivocal new lesions.	Time from randomization/start of study treatment to BICR assessed progressive disease per RECIST1.1 or death, assessed for up to 5.6 years.
Overall Survival (OS); Target Population Analysis Set	Overall Survival (OS) from all-cause mortality	Time from randomization/start of study treatment to all-cause death, assessed for up to 5.6 years.
Objective Response Rate (ORR) by Investigator Assessment; Contribution of Components Analysis Set	Percentage of subjects with a confirmed Objective Response (OR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). OR includes Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in target lesion diameters). OR must be recorded at one visit and confirmed by repeat imaging at least 4 weeks later, with no disease progression between initial and confirmation visits.	Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years.
Objective Response Rate (ORR) by BICR Assessment; Contribution of Components Analysis Set	Percentage of subjects with a confirmed Objective Response (OR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). OR includes Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in target lesion diameters). OR must be recorded at one visit and confirmed by repeat imaging at least 4 weeks later, with no disease progression between initial and confirmation visits.	Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years.
Duration of Response (DoR) by Investigator Assessment; Contribution of Components Analysis Set	Median time of response for patients with an investigator assessed confirmed objective response per RECIST1.1	From date of first confirmed objective response to progressive disease in accordance with RECIST1.1 or death from any cause, whichever came first; assessed for up to 5.6 years.
Duration of Response (DoR) by BICR Assessment; Contribution of Components Analysis Set	Median time of response for patients with an investigator assessed confirmed objective response per RECIST1.1	From date of first confirmed objective response to progressive disease in accordance with RECIST1.1 or death from any cause, whichever came first; assessed for up to 5.6 years.
Progression-free Survival (PFS) by Investigator Assessment; Contribution of Components Analysis Set	Median progression-free survival (PFS) was measured by investigator assessment using RECIST 1.1 and the Kaplan-Meier method. Progressive disease (PD) per RECIST 1.1 is defined as at least a 20% increase in the sum of target lesion diameters (with an absolute increase of ≥5 mm); unequivocal progression of non-target lesions, which may result from marked progression in a single lesion or multiple lesions; or the appearance of one or more unequivocal new lesions.	Time from randomization/start of study treatment to investigator assess progressive disease per RECIST1.1 or death, assessed for up to 5.6 years.
Progression-free Survival (PFS) by BICR Assessment; Contribution of Components Analysis Set	Median progression-free survival (PFS) was measured by BICR assessment using RECIST 1.1 and the Kaplan-Meier method. Progressive disease (PD) per RECIST 1.1 is defined as at least a 20% increase in the sum of target lesion diameters (with an absolute increase of ≥5 mm); unequivocal progression of non-target lesions, which may result from marked progression in a single lesion or multiple lesions; or the appearance of one or more unequivocal new lesions.	Time from randomization/start of study treatment to BICR assessed progressive disease per RECIST1.1 or death, assessed for up to 5.6 years.
Objective Response Rate (ORR) by Investigator Assessment; Safety Analysis Set	Percentage of subjects with a confirmed Objective Response (OR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). OR includes Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in target lesion diameters). OR must be recorded at one visit and confirmed by repeat imaging at least 4 weeks later, with no disease progression between initial and confirmation visits.	Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years.
Objective Response Rate (ORR) by BICR Assessment; Safety Analysis Set	Percentage of subjects with a confirmed Objective Response (OR) per Response Evaluation Criteria In Solid Tumors (RECIST 1.1). OR includes Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: ≥30% decrease in target lesion diameters). OR must be recorded at one visit and confirmed by repeat imaging at least 4 weeks later, with no disease progression between initial and confirmation visits.	Time from randomization/first dose of study treatment to progression or last evaluable assessment in the absence of progressionuntil the end of the study, or an approximate maximum of 5.6 years.
Duration of Response (DoR) by Investigator Assessment; Safety Analysis Set	Median time of response for patients with an investigator assessed confirmed objective response per RECIST1.1	From date of first confirmed objective response to progressive disease in accordance with RECIST1.1 or death from any cause, whichever came first; assessed for up to 5.6 years.
Duration of Response (DoR) by BICR Assessment; Safety Analysis Set	Median time of response for patients with an investigator assessed confirmed objective response per RECIST1.1	From date of first confirmed objective response to progressive disease in accordance with RECIST1.1 or death from any cause, whichever came first; assessed for up to 5.6 years.
Overall Survival (OS); Safety Analysis Set	Overall Survival (OS) from all-cause mortality	Time from randomization/start of study treatment to all-cause death, assessed for up to 5.6 years.
Progression-free Survival (PFS) by Investigator Assessment; Safety Analysis Set	Median progression-free survival (PFS) was measured by investigator assessment using RECIST 1.1 and the Kaplan-Meier method. Progressive disease (PD) per RECIST 1.1 is defined as at least a 20% increase in the sum of target lesion diameters (with an absolute increase of ≥5 mm); unequivocal progression of non-target lesions, which may result from marked progression in a single lesion or multiple lesions; or the appearance of one or more unequivocal new lesions.	Time from randomization/start of study treatment to investigator assess progressive disease per RECIST1.1 or death, assessed for up to 5.6 years.
Progression-free Survival (PFS) by BICR Assessment; Safety Analysis Set	Median progression-free survival (PFS) was measured by BICR assessment using RECIST 1.1 and the Kaplan-Meier method. Progressive disease (PD) per RECIST 1.1 is defined as at least a 20% increase in the sum of target lesion diameters (with an absolute increase of ≥5 mm); unequivocal progression of non-target lesions, which may result from marked progression in a single lesion or multiple lesions; or the appearance of one or more unequivocal new lesions.	Time from randomization/start of study treatment to BICR assessed progressive disease per RECIST1.1 or death, assessed for up to 5.6 years.

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
CNS PFS by BICR assessments in accordance with RECIST 1.1	To assess the efficacy of savolitinib plus osimertinib and savolitinib plus placebo, respectively, on CNS metastases in patients with CNS metastases at baseline.	Up to 15 months after the last patient under CSP version 7.0 has been randomised to treatment
The presence/absence of CNS lesions at progression by BICR assessments in accordance with RECIST 1.1	To assess the efficacy of savolitinib plus osimertinib and savolitinib plus placebo, respectively, on the prevention of CNS metastases in patients without CNS metastases at baseline.	Up to 15 months after the last patient under CSP version 7.0 has been randomised to treatment
PRO CTCAE symptoms	To assess the impact of savolitinib in combination with osimertinib on patient reported treatment-related symptoms.	From date of consent until the date of first documented progression, up to approximately 36 months.
Patient's Global Impression of Severity (PGIS)	To assess patients' overall impression of severity of cancer symptoms. In patients centrally confirmed as MET positive in all patients.	From date of consent until the date of first documented progression, up to approximately 36 months.
EQ-5D-5L	To explore the impact of treatment and disease on health state utility. In patients centrally confirmed as MET positive in all patients.	From date of consent until the date of first documented progression, up to approximately 36 months.
Longitudinal changes in circulating DNA and/or RNA compared with PFS, OS and ORR.	To assess the predictive value of changes in circulating biomarkers on clinical efficacy endpoints.	Blood samples collected at Screening within 28 days before the first dose of study treatment; on day of first dose of study treatment; at discontinuation 7 days after last dose of study treatment. (One cycle = 28 days)
Pharmacogenetic analyses on blood samples.	To collect and store DNA (according to each country's local and ethical procedures) for future exploratory research into genes/genetic variation that may influence response (ie, distribution, safety, tolerability and efficacy) to study treatments and or susceptibility to disease (optional).	Screening within 28 days before first dose; at first dose; 7 days after last dose. (One cycle = 28 days)
Disease relevant or response markers in tumour tissue and circulating tumour DNA/RNA including but not limited to EGFR mutations and MET amplifications.	To collect and store tissue, plasma and serum samples for diagnostic development and exploratory analyses.	Screening within 28 days before first dose; at first dose; 7 days after last dose. Tumour tissue collected during Pre-screening and at treatment discontinuation 7 days after last dose. (One cycle = 28 days)
HLA alleles associated with susceptibility to drug related AEs (such as but not limited to hypersensitivity).	To collect and store germline DNA for exploration of the role of HLA alleles in developmental toxicity.	On first day of study treatment at Cycle 1 Day 1. (One cycle = 28 days)

Collaborators and Investigators

• Sponsor: AstraZeneca
• Collaborators: Hutchison Medipharma Limited
• Investigators: Principal Investigator: Lecia V Sequist, MD MPH, Massachusetts General Hospital; Principal Investigator: Myung-Ju Ahn, MD, Samsung Medical Centre Sungkyunkwan University School of Medicine

Publications and helpful links

General Publications

• Schmid S, Fruh M, Peters S. Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice? Lancet Oncol. 2020 Mar;21(3):320-322. doi: 10.1016/S1470-2045(19)30859-9. Epub 2020 Feb 3. No abstract available.
• Yang JC, Chen YM, Batra U, Do KH, Sitthideatphaiboon P, Danchaivijitr P, Lee KY, Chindaprasirt J, Yang CT, Chang GC, Charoentum C, Ungtrakul T, Moran JIH, Hartmaier R, Igwegbe I, Gont A, Haskins M, Xu W, Riess JW. Savolitinib Plus Osimertinib in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Advanced Non-Small Cell Lung Cancer: A Randomized Phase II trial. Clin Lung Cancer. 2026 Jan;27(1):38-46. doi: 10.1016/j.cllc.2025.10.018. Epub 2025 Oct 22.

Helpful Links

• Redacted Statistical Analysis Plan (SAP)
• Redacted CSR Synopsis
• Redacted CSP

Study record dates

Study Major Dates

• Study Start (Actual): January 9, 2019
• Primary Completion (Actual): August 23, 2024
• Study Completion (Estimated): December 31, 2026

Study Registration Dates

• First Submitted: November 30, 2018
• First Submitted That Met QC Criteria: December 14, 2018
• First Posted (Actual): December 19, 2018

Study Record Updates

• Last Update Posted (Actual): April 23, 2026
• Last Update Submitted That Met QC Criteria: April 21, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: Non Small Cell Lung Cancer; Osimertinib; AZD9291; epidermal growth factor receptor mutation positive; hepatocyte growth factor receptor; savolitinib; AZD6094; volitinib
• Additional Relevant MeSH Terms: Neoplasms by Site; Neoplasms; Respiratory Tract Diseases; Neoplasms by Histologic Type; Lung Diseases; Neoplasms, Glandular and Epithelial; Respiratory Tract Neoplasms; Thoracic Neoplasms; Lung Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Carcinoma; Carcinoma, Non-Small-Cell Lung; Tyrosine Kinase Inhibitors; Antineoplastic Agents; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Protein Kinase Inhibitors; osimertinib; 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
• Other Study ID Numbers: D5084C00007; 2018-003012-51 (EudraCT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• IPD Sharing Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• IPD Sharing Access Criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No